Abstract
P151 - Lenvatinib plus Pembrolizumab as first-line treatment in patients with advanced renal cell carcinoma – real world data from a retrospective multi-center analysis
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
